70 related articles for article (PubMed ID: 23499398)
1. A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.
Alrifai D; Popat S; Ahmed M; Gonzalez D; Nicholson AG; Parcq Jd; Benepal T
Lung Cancer; 2013 Jun; 80(3):339-40. PubMed ID: 23499398
[TBL] [Abstract][Full Text] [Related]
2. BRAF-mutations in non-small cell lung cancer.
Brustugun OT; Khattak AM; Trømborg AK; Beigi M; Beiske K; Lund-Iversen M; Helland Å
Lung Cancer; 2014 Apr; 84(1):36-8. PubMed ID: 24552757
[TBL] [Abstract][Full Text] [Related]
3. Rare mutations in non-small-cell lung cancer.
D'Arcangelo M; D'Incecco A; Cappuzzo F
Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
[TBL] [Abstract][Full Text] [Related]
5. New driver mutations in non-small-cell lung cancer.
Pao W; Girard N
Lancet Oncol; 2011 Feb; 12(2):175-80. PubMed ID: 21277552
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer.
Goldman JM; Gray JE
Cancer Genet; 2015 Jun; 208(6):351-4. PubMed ID: 26066373
[TBL] [Abstract][Full Text] [Related]
7. ALK-rearranged adenosquamous lung cancer presenting as squamous cell carcinoma: a potential challenge to histologic type triaging of NSCLC biopsies for molecular studies.
Dragnev KH; Gehr G; Memoli VA; Tafe LJ
Clin Lung Cancer; 2014 May; 15(3):e37-40. PubMed ID: 24524823
[No Abstract] [Full Text] [Related]
8. Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
Yoshida A; Tsuta K; Nakamura H; Kohno T; Takahashi F; Asamura H; Sekine I; Fukayama M; Shibata T; Furuta K; Tsuda H
Am J Surg Pathol; 2011 Aug; 35(8):1226-34. PubMed ID: 21753699
[TBL] [Abstract][Full Text] [Related]
9. Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF.
Giroux S
Bioorg Med Chem Lett; 2013 Jan; 23(2):394-401. PubMed ID: 23245516
[TBL] [Abstract][Full Text] [Related]
10. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
Cooper WA; O'toole S; Boyer M; Horvath L; Mahar A
Pathology; 2011 Feb; 43(2):103-15. PubMed ID: 21233671
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
12. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
14. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
15. A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?
Schlick K; Troch M; Placher-Sorko G; Faber V; Neureiter D; Berghoff AS; Preusser M; Greil R; Hopfinger G
Ann Hematol; 2015 Feb; 94(2):345-6. PubMed ID: 25055797
[No Abstract] [Full Text] [Related]
16. Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation.
Ko YS; Hwang TS; Han HS; Lim SD; Kim WS; Oh SY
Pathol Int; 2012 Jan; 62(1):43-8. PubMed ID: 22192803
[TBL] [Abstract][Full Text] [Related]
17. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
18. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
19. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
Giordano TJ; Kuick R; Thomas DG; Misek DE; Vinco M; Sanders D; Zhu Z; Ciampi R; Roh M; Shedden K; Gauger P; Doherty G; Thompson NW; Hanash S; Koenig RJ; Nikiforov YE
Oncogene; 2005 Oct; 24(44):6646-56. PubMed ID: 16007166
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Soares P; Trovisco V; Rocha AS; Lima J; Castro P; Preto A; Máximo V; Botelho T; Seruca R; Sobrinho-Simões M
Oncogene; 2003 Jul; 22(29):4578-80. PubMed ID: 12881714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
